Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Bruno Lucidi is Director at Atea Pharmaceuticals. OQRO lists 10 transactions filed with the SEC under this name, the latest on Nov 20, 2026, each linked to the official Form 4.
Director
Disclosures on record
10
Companies involved
1
Atea PharmaceuticalsAVIR
10 disclosures · Jun 2026 – Nov 2026 · 2 sold
Nov 19, 2026Sold~$89Kdisclosed Nov 20
DetailsOfficial recordNov 17, 2026Sold~$27Kdisclosed Nov 20
DetailsNov 17, 202622Kdisclosed Nov 20
DetailsOfficial recordNov 19, 202653Kdisclosed Nov 20
DetailsOfficial recordNov 17, 202622Kdisclosed Nov 20
DetailsOfficial recordNov 19, 202653Kdisclosed Nov 20
DetailsOfficial recordJun 18, 202627Kdisclosed Jun 24
DetailsOfficial recordJun 18, 202638Kdisclosed Jun 24
DetailsOfficial recordJun 18, 202630Kdisclosed Jun 24
DetailsOfficial recordJun 18, 202630Kdisclosed Jun 24
DetailsOfficial recordBruno Lucidi has no open-market purchase on record since 2026. Sales in 1 of the 1 years since 2026.
Bruno Lucidi reported 0 open-market purchases and 2 sales since 2026; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $116K2×2 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
As of the latest filing on , Bruno Lucidi reported holding 187,990 shares of Atea Pharmaceuticals (AVIR), worth about $744K at the last close of $4 (Nov 20, 2026). In the last 12 months, Bruno Lucidi sold $116K in 2 sales.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Atea Pharmaceuticals AVIR | 187,990 | 188K direct | $4 | $744K | Nov 19, 2026 |
Is this Bruno Lucidi’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Nov 19, 2026, Bruno Lucidi reported holding 187,990 shares of Atea Pharmaceuticals (AVIR). At the last close of $4 on Nov 20, 2026, that is about $744K. This is the stake disclosed in filings, not a net worth.
No public filing gives Bruno Lucidi's net worth. What SEC Form 4 shows is the stock stake: 187,990 shares of Atea Pharmaceuticals (AVIR), about $744K at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
In SEC filings of the last 12 months, Bruno Lucidi reported 2 open-market sales worth $116K, and no open-market purchase. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Bruno Lucidi has no open-market purchase on record since 2026. Sales in 1 of the 1 years since 2026.
In SEC filings since 2026: no open-market purchase is on record; the latest open-market sale is from 2026.
Atea Pharmaceuticals (AVIR), from 2026 to 2026: 0 purchases and 2 sales.
Bruno Lucidi reported 0 open-market purchases and 2 sales here, 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.